^
    Back
    Association details:
    Biomarker:MET mutation
    Cancer:Renal Cell Carcinoma
    Drug:Sutent (sunitinib) (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2020
    Title:

    MET status and treatment outcomes in papillary renal cell carcinoma (PRCC): Pooled analysis of historical data.

    Published date:
    05/28/2020
    Excerpt:
    In sunitinib-treated pts, PFS and TTF were numerically longer in pts with MET-driven tumors vs pts with MET-ind tumors, but OS was similar (Table)
    DOI:
    10.1200/JCO.2020.38.15_suppl.e19321